Previous Close | 73.01 |
Open | 73.25 |
Bid | 72.00 x 100 |
Ask | 77.01 x 100 |
Day's Range | 73.20 - 73.87 |
52 Week Range | 71.37 - 87.87 |
Volume | |
Avg. Volume | 7,612,972 |
Market Cap | 91.253B |
Beta (5Y Monthly) | 0.20 |
PE Ratio (TTM) | 16.28 |
EPS (TTM) | 4.50 |
Earnings Date | Apr 25, 2024 - Apr 29, 2024 |
Forward Dividend & Yield | 3.08 (4.21%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | 78.51 |
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
FOSTER CITY, Calif., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
FOSTER CITY, Calif. & WALTHAM, Mass., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.